A Research Guide for
Chronic Migraine

It is worth understanding which migraine pattern you have, because a few distinctions change treatment in concrete, safety-relevant ways. The most important is whether you have migraine with aura — the temporary visual zig-zags, blind spots, or tingling that precede or accompany some attacks. Aura is not dangerous in itself, but it carries one critical implication: people who have migraine with aura should generally not use estrogen-containing birth control (combined pills, patch, or ring), because the combination modestly raises the risk of stroke. If you have aura and are using or considering estrogen contraception, that is a specific conversation to have with your clinician about safer alternatives.

Two rarer subtypes also change the rules. Hemiplegic migraine (with temporary weakness on one side) and migraine with brainstem aura are reasons to avoid the triptan and ergot acute medicines that most people use, so they require a different acute plan — another reason an accurate label matters. And the distinction between chronic migraine (15 or more headache days a month) and episodic migraine determines eligibility for treatments such as Botox, which is approved only for the chronic form.

The practical takeaway is not that you need to become a diagnostician, but that the details you report — especially any aura, any one-sided weakness, and an honest count of your headache days — directly steer which treatments are safe and available to you. Describing your attacks precisely is one of the most useful things you can do at an appointment.

Roughly two-thirds of migraine patients have migraine without aura. The remaining one-third experience aura — most commonly visual disturbances (scintillating scotomas, fortification spectra, or visual field deficits) that develop gradually over 5–20 minutes and resolve within 60 minutes, typically followed by the headache phase.

Migraine with aura has specific implications:

• Combined oral contraceptives containing estrogen are generally contraindicated in migraine with aura due to a small but real increased risk of ischemic stroke.
• The aura itself can sometimes occur without the headache (“acephalgic migraine” or “migraine aura without headache”), which can be concerning and is sometimes mistaken for transient ischemic attack (TIA).
• Frequent aura may itself be a treatment target — lamotrigine has evidence specifically for reducing aura frequency.

This subtype involves aura symptoms originating from the brainstem or both hemispheres simultaneously: vertigo, tinnitus, hearing loss, double vision, ataxia, decreased consciousness, or bilateral visual symptoms. Triptans and ergotamines have historically been avoided in this subtype due to theoretical vascular concerns, though recent expert opinion has softened this restriction for triptans. Diagnosis requires at least two brainstem aura symptoms.

Hemiplegic migraine involves temporary motor weakness (hemiplegia or hemiparesis) as part of the aura, usually lasting less than 72 hours. It can be familial (linked to specific ion channel gene mutations — CACNA1A, ATP1A2, SCN1A) or sporadic. The weakness can be frightening and is sometimes mistaken for stroke. Triptans and ergotamines are traditionally avoided. Diagnosis requires careful exclusion of other causes of transient weakness.

Vestibular migraine is one of the most common causes of episodic vertigo. It involves moderate to severe vestibular symptoms (spontaneous vertigo, positional vertigo, visually induced vertigo, head-motion-induced vertigo) lasting between 5 minutes and 72 hours, associated with migraine features. It may occur with or without headache.

Vestibular migraine is frequently misdiagnosed as Meniere disease, benign paroxysmal positional vertigo (BPPV), or anxiety. Diagnostic criteria were established jointly by the International Headache Society and the Barany Society. Treatment follows the same principles as other migraine — lifestyle modification, vestibular rehabilitation, and preventive medications.

Pure menstrual migraine occurs exclusively in the window from 2 days before to 3 days after menstruation onset. Menstrually related migraine occurs in this window but also at other times. These attacks tend to be longer, more severe, and more resistant to treatment than non-menstrual attacks, driven by the estrogen withdrawal that occurs with menses.

Treatment strategies include perimenstrual mini-prophylaxis (scheduled triptans or NSAIDs around the menstrual window), continuous hormonal contraception (to eliminate the estrogen drop), and standard preventive therapy. CGRP monoclonal antibodies have shown particular efficacy for menstrual migraine in subgroup analyses.

The biology of migraine isn't just background — it explains, in plain terms, why the modern approach to treatment looks the way it does, and understanding it helps you be an active partner in your care. Migraine is now understood as a disorder of an over-excitable brain and its pain-signaling system, not a problem of blood vessels and not a sign of weakness or poor stress tolerance. That reframing matters: it is why migraine is treated as a legitimate neurological disease, and why the goal is to calm an over-reactive system rather than simply to mask pain.

Two features of that biology have direct, practical consequences for you. First, a key trigger molecule called CGRP sits at the center of the attack — which is exactly why the newest and best-tolerated treatments are the ones that block it. When your clinician suggests a CGRP medicine, they are aiming at the mechanism of your disease, not guessing. Second, attacks involve the nervous system becoming progressively “wound up” (sensitization) as they go on — the biological reason to treat early, before that wind-up makes an attack hard to stop, and the reason frequent untreated attacks can, over time, push migraine from occasional to chronic.

This last point is the most empowering: because chronification is partly driven by things that can be changed — frequent attacks, overused acute medicine, poor sleep, untreated depression — the process can often be slowed or reversed. Effective prevention and good attack control aren't only about feeling better today; they may genuinely change the long-term course of your disease.

The trigeminal nerve is the largest cranial nerve and provides sensation to the face, head, and meninges (the membranes surrounding the brain). In migraine, trigeminal nerve fibers surrounding cerebral blood vessels become activated, releasing inflammatory neuropeptides — most importantly calcitonin gene-related peptide (CGRP).

CGRP is a potent vasodilator and pain signaling molecule. During a migraine attack, CGRP levels rise dramatically in the jugular blood. The discovery of CGRP’s central role in migraine led directly to two classes of breakthrough therapies:

• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) — large molecules that block CGRP or its receptor, used as monthly or quarterly preventive injections or infusions.
• Gepants (ubrogepant, rimegepant, atogepant, zavegepant) — small-molecule CGRP receptor antagonists, used as oral or nasal acute treatments and, in some cases, as preventives.

The aura phase of migraine is caused by cortical spreading depression (CSD) — a slowly propagating wave of neuronal depolarization followed by suppression that moves across the cortex at roughly 3 mm per minute. This electrical event explains why visual aura symptoms expand gradually across the visual field and why sensory aura marches from finger to hand to arm to face. CSD can also activate the trigeminovascular system, helping to trigger the headache phase.

In chronic migraine, repeated activation of pain pathways leads to central sensitization — the brain’s pain processing system becomes amplified and more easily triggered. This manifests as cutaneous allodynia (pain from normally non-painful stimuli like combing hair, wearing glasses, or touching the scalp), lower pain thresholds between attacks, and attacks that are triggered by stimuli that would not have triggered them earlier in the disease.

Central sensitization is why chronic migraine is harder to treat than episodic migraine, why early and aggressive treatment of episodic migraine matters (to prevent progression), and why treatments like onabotulinumtoxinA (Botox) — which reduces peripheral sensitization of trigeminal nerve fibers — are effective specifically in chronic migraine.

Requires at least 5 attacks fulfilling all of the following:

• Headache lasting 4–72 hours (untreated or unsuccessfully treated)
• At least two of: unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity
• During the headache, at least one of: nausea and/or vomiting, photophobia and phonophobia
• Not better accounted for by another ICHD-3 diagnosis

Requires all of the following:

• Headache (migraine-like or tension-type-like) on 15 or more days per month for more than 3 months
• Occurring in a patient who has had at least 5 attacks fulfilling criteria for migraine without aura (1.1) and/or migraine with aura (1.2)
• On at least 8 days per month for more than 3 months, the headache has migraine features, or the patient believes it is migraine and is relieved by a triptan or ergot derivative
• Not better accounted for by another ICHD-3 diagnosis

Two validated questionnaires help quantify migraine disability and guide treatment decisions:

• MIDAS (Migraine Disability Assessment): Measures days of reduced function over the past 3 months in work/school, household chores, and social/leisure activities. A MIDAS score above 20 indicates severe disability and typically warrants preventive treatment.
• HIT-6 (Headache Impact Test): A 6-question survey measuring pain, functioning, vitality, and emotional distress. Scores above 60 indicate substantial impact.

These scores are useful for insurance pre-authorization (many insurers require documented disability scores for CGRP therapy approval) and for tracking treatment response over time.

The SNOOP mnemonic helps identify when imaging is needed:

• Systemic symptoms or signs (fever, weight loss, cancer history, immunodeficiency)
• Neurological signs (papilledema, focal deficits, altered mental status)
• Onset sudden (“thunderclap” headache reaching maximum intensity in seconds) — subarachnoid hemorrhage must be excluded
• Onset after age 50 (giant cell arteritis, mass lesion, subdural hematoma)
• Pattern change (first or worst headache, progressive worsening, headache that is fundamentally different from the patient’s established pattern)

MRI of the brain with and without contrast is the preferred imaging modality for headache evaluation. CT is faster and more available for emergency settings (e.g., thunderclap headache where subarachnoid hemorrhage is the concern).

If you have an established migraine pattern that has not changed, normal neurological examination, and no red flags — routine imaging is not recommended and rarely changes management.

• Medication overuse headache (MOH): Discussed in its own section below. Coexists with chronic migraine in a large proportion of patients and must be addressed for treatment to succeed.
• New daily persistent headache (NDPH): Daily headache from onset, often pinpointed to a specific day. Different prognosis and treatment trajectory from chronic migraine.
• Tension-type headache: Bilateral, pressing/tightening, mild to moderate, not worsened by activity, without nausea or combined photophobia/phonophobia. Can coexist with migraine.
• Cluster headache: Strictly unilateral, excruciating, periorbital/temporal, short duration (15–180 minutes), with ipsilateral autonomic features (tearing, nasal congestion, ptosis). Attacks occur in bouts. Different biology and different treatment from migraine.
• Hemicrania continua: Strictly unilateral, continuous headache with fluctuating intensity and autonomic features. Responds completely to indomethacin — an indomethacin trial is both diagnostic and therapeutic.
• Idiopathic intracranial hypertension (IIH): Headache with papilledema, visual obscurations, and pulsatile tinnitus. More common in women of childbearing age with elevated BMI. Diagnosed by lumbar puncture showing elevated opening pressure.
• Cervicogenic headache: Headache originating from disorders of the cervical spine or its soft tissues. Triggered by neck movement or sustained posture. Does not respond to migraine-specific treatment.

• Do I meet the ICHD-3 criteria for chronic migraine, or could this be another headache disorder?
• Do I need brain imaging? If not, why not — and what would change your mind?
• Could my headaches have a secondary cause (medication overuse, sleep apnea, idiopathic intracranial hypertension)?
• What is my MIDAS or HIT-6 score, and what does it mean for my treatment plan?
• Am I overusing acute medications? How many days per month am I using them?
• Should I be screened for depression, anxiety, or sleep disorders that may be worsening my migraine?

The cruelest feature of chronic migraine is that the medicines you take to relieve attacks can, with frequent use, start causing them. This is medication-overuse headache (sometimes called “rebound”), and it is a trap precisely because every step feels reasonable: you have a headache, you treat it, it comes back, you treat it again. Over weeks and months the pain system resets at a lower threshold, and you end up with more headaches and more medication, locked together. It is nobody's fault — it is a predictable effect of the medication, not a sign of weakness or “dependence” in the ordinary sense.

Knowing the rough day-limits helps you spot the trap before it closes: simple painkillers (acetaminophen, ibuprofen, aspirin) become a problem above about 15 days a month, while triptans, combination pills, opioids, and butalbital products do so above about 10 days a month. If you are near or over these, that is the conversation to have with your clinician — not as a confession, but as the key that unlocks progress.

The genuinely good news is that the old, dreaded approach — “tough out a painful withdrawal first, then maybe start prevention” — is no longer how this is done. Modern practice (reflected in 2024 guidance) starts an effective preventive, often a CGRP medicine or Botox, at the same time as cutting back the overused medicine, because these preventives work even while overuse is being addressed. There is usually a week or two of temporary worsening as the overused drug is reduced, which your clinician can ease with a short bridging treatment — but on the other side, many people find their headaches drop dramatically. Breaking the rebound cycle is often the single most powerful step in turning chronic migraine back into occasional migraine.

The ICHD-3 defines medication overuse based on days of use per month (not doses per day):

• Simple analgesics (acetaminophen, NSAIDs): 15 or more days per month for more than 3 months
• Triptans: 10 or more days per month for more than 3 months
• Opioids: 10 or more days per month for more than 3 months
• Combination analgesics (e.g., butalbital-containing compounds): 10 or more days per month for more than 3 months
• Ergotamines: 10 or more days per month for more than 3 months
• Any combination of the above: 10 or more days per month for more than 3 months

Note: the gepants (ubrogepant, rimegepant) appear to have a lower risk of causing MOH, based on current evidence, though this remains an area of active study.

The approach to MOH depends on the class of medication being overused:

• Triptans and NSAIDs: Can often be discontinued abruptly with a short bridge of steroids or a different acute class. A structured withdrawal plan supervised by the headache specialist is recommended.
• Opioids and butalbital compounds: Usually require gradual tapering, often in conjunction with a pain specialist. Abrupt discontinuation can cause withdrawal symptoms. These are the medications most strongly associated with MOH and are generally not recommended for migraine treatment.
• Bridge strategies during withdrawal: Short courses of corticosteroids (prednisone or dexamethasone), nerve blocks (greater occipital nerve blocks), and starting a preventive medication concurrently.

Most patients improve significantly within 2–3 months of eliminating overuse, but the withdrawal period can be difficult. Headaches often worsen temporarily (a “washout” period of 1–2 weeks) before improving. Preventive therapy should be started simultaneously — not after the withdrawal is complete.

The most important thing patients can do: track their acute medication days. If they are using any acute headache medication 10 or more days per month, this conversation needs to happen with their provider.

Two practical ideas make acute treatment work far better, and both are easy to get wrong. The first is treat early. A migraine becomes harder to stop once it is fully established — the nervous system becomes “wound up” (a process called central sensitization, often felt as your scalp or skin becoming tender), and the same medicine that would have aborted the attack at the first twinge may barely touch it an hour later. The most common reason people think a migraine drug “doesn't work” is that it was taken too late. Treat at mild pain, keep your medication with you, and don't wait to “see if it becomes a bad one.”

The second idea is that there are now good options even if you can't take a triptan. Triptans (sumatriptan, rizatriptan, and the others) are excellent for many people, but because they gently narrow blood vessels they are not safe for people with heart disease, a prior stroke or mini-stroke, poorly controlled blood pressure, or certain other vascular conditions. For decades those patients had little to use. That has changed: the gepants (ubrogepant, rimegepant, and the nasal spray zavegepant) and the ditan lasmiditan relieve attacks without narrowing blood vessels, so they are options when triptans are off-limits. If you've been told you can't take triptans, ask specifically about these.

A few cautions complete the picture. Keep acute-medication use to fewer than about 10 days a month (for triptans, combination pills, and opioids) to avoid the rebound trap described below. And avoid opioids and butalbital-containing pills (such as those with the brand component “Fioricet”) for migraine altogether — they don't treat the migraine specifically, they're the medications most likely to drive occasional migraine into daily migraine, and they carry dependence risk. If you're relying on them, that's a conversation to have with your clinician about safer, more effective alternatives.

Triptans (5-HT1B/1D receptor agonists) have been the most effective and widely used acute migraine treatment since sumatriptan was introduced in 1991. Seven triptans are available: sumatriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, eletriptan, and frovatriptan. They differ in onset, duration, and formulation (tablets, nasal sprays, injections, dissolvable tablets).

• Fastest onset: Sumatriptan injection (6 mg subcutaneous — works in 10–15 minutes), sumatriptan or zolmitriptan nasal spray
• Most effective oral: Eletriptan 40–80 mg and rizatriptan 10 mg generally rate highest in head-to-head comparisons
• Longest-acting (fewer recurrences): Frovatriptan and naratriptan — useful for menstrual migraine mini-prophylaxis

Key limitations: Contraindicated in uncontrolled hypertension, coronary artery disease, prior stroke or TIA, peripheral vascular disease, and (traditionally) migraine with brainstem aura or hemiplegic migraine. Overuse can cause MOH. Cannot be combined with ergotamines or MAOIs.

Many patients try one triptan, find it ineffective, and conclude “triptans don’t work for me.” This is often incorrect — response varies significantly between individual triptans. A trial of at least two different triptans in appropriate doses and formulations is recommended before concluding this class has failed.

Gepants represent the first new class of acute migraine-specific treatment in three decades. They block the CGRP receptor without causing vasoconstriction, making them an option for patients with cardiovascular risk factors who cannot take triptans.

• Ubrogepant (Ubrelvy): FDA-approved December 2019. Oral tablet (50 mg or 100 mg). Demonstrated superiority over placebo for 2-hour pain freedom and freedom from the most bothersome symptom in the ACHIEVE-1 (NCT02828020) and ACHIEVE-2 (NCT02867709) trials. May take a second dose if needed after 2 hours. Metabolized by CYP3A4 — dose adjustments needed with moderate CYP3A4 inhibitors; avoid with strong CYP3A4 inhibitors.
• Rimegepant (Nurtec ODT): FDA-approved February 2020 for acute use, May 2021 for preventive use. Orally disintegrating tablet (75 mg) — dissolves on the tongue without water. Proven effective in the Study 301 (NCT03237845) trial. Unique dual indication: can be used both as an acute treatment (as needed) and as a preventive (75 mg every other day). This dual role is useful for patients with high-frequency episodic or chronic migraine, potentially reducing the number of medications needed.
• Zavegepant (Zavzpret): FDA-approved March 2023. Nasal spray (10 mg). The first intranasal gepant. Rapid onset due to nasal absorption — useful for patients with nausea or those who need faster relief than oral options. Demonstrated efficacy in the BHV3500-301 (NCT04571060) trial.

Gepants do not appear to cause MOH at the same rate as triptans and NSAIDs, based on open-label extension data, though longer-term surveillance is ongoing. They represent a genuinely new approach to acute migraine treatment.

Lasmiditan (Reyvow) is a selective serotonin 5-HT1F receptor agonist — FDA-approved October 2019. Unlike triptans, it does not cause vasoconstriction, making it safe in patients with cardiovascular disease. Proven effective in the SAMURAI (NCT02439320) and SPARTAN (NCT02605174) trials.

Key considerations:

• Available as 50 mg, 100 mg, and 200 mg oral tablets
• Causes CNS effects: dizziness, sedation, fatigue. Patients must not drive or operate machinery for at least 8 hours after dosing (Schedule V controlled substance)
• No cardiovascular contraindications
• Useful specifically for patients with migraine who have cardiovascular risk factors or contraindications to triptans

Over-the-counter options remain effective for many attacks, especially mild-to-moderate ones treated early:

• Ibuprofen (400–800 mg), naproxen sodium (500–550 mg): Well-studied first-line options. Naproxen has a longer duration that may reduce recurrence.
• Aspirin (900–1000 mg): Effective at high doses for individual attacks.
• Acetaminophen (1000 mg): Less effective than NSAIDs for most patients but an option when NSAIDs are contraindicated (e.g., renal disease, GI bleeding history).
• Combination analgesics: Acetaminophen/aspirin/caffeine (Excedrin Migraine) is FDA-approved for migraine and effective in clinical trials. The caffeine component enhances absorption and analgesic effect but contributes to MOH risk.

Stratified approach: For mild-to-moderate attacks, NSAIDs may be sufficient. For moderate-to-severe attacks or attacks that do not respond to NSAIDs, triptans or gepants are more appropriate. Combining a triptan with an NSAID (e.g., sumatriptan plus naproxen) is a well-supported strategy for severe attacks.

Nausea and gastroparesis (slowed stomach emptying) are common during migraine and can prevent oral medications from being absorbed effectively. Anti-emetics serve double duty — treating nausea and functioning as mild analgesic adjuncts:

• Metoclopramide (10 mg): Prokinetic — enhances gastric emptying and improves oral drug absorption. Has intrinsic analgesic effect for migraine. Often used in emergency department migraine protocols.
• Prochlorperazine (10 mg) and chlorpromazine (0.1 mg/kg IV): Dopamine antagonists with strong anti-nausea and analgesic effects. Used in acute/ER settings.
• Ondansetron (4–8 mg): Commonly used for nausea, though less evidence specifically for migraine than the dopamine antagonists.

For patients whose nausea prevents them from taking oral medications, non-oral routes are essential: sumatriptan injection, zolmitriptan nasal spray, zavegepant nasal spray, prochlorperazine suppositories, or neuromodulation devices.

• Opioids: Generally not recommended for migraine. They do not address the underlying pathophysiology, increase the risk of MOH, increase the risk of chronic migraine progression, and interfere with other migraine therapies. The AHS position statement recommends against routine opioid use for migraine.
• Butalbital-containing compounds (Fioricet, Fiorinal): High MOH risk, dependency risk, and limited evidence of efficacy beyond simpler analgesics. Not recommended by headache guidelines.
• Ergotamines: Largely superseded by triptans. Higher side-effect burden, more drug interactions, and easier to overuse.

Preventive medicines don't stop migraines overnight, and the single biggest reason people give up on one too soon is expecting them to. Most preventives — the CGRP medicines, Botox, and the older pills alike — need a fair trial before you can judge them: about three months for most, and a full two rounds (about six months) for Botox, whose effect builds gradually. Stopping at three or four weeks discards medicines that would have helped. Agree with your clinician at the start on how long you'll give it, so a slow start doesn't feel like failure.

The most useful thing you can do is keep a headache diary — a simple record of which days you have a headache, how bad it is, and what medicine you took. It does three jobs at once: it tells you and your clinician whether a treatment is genuinely reducing your headache days (memory is surprisingly unreliable here), it is often required by insurers before they will approve Botox or CGRP therapy, and it catches medication overuse before it derails everything. Many people use a free phone app.

Define success honestly. The standard goal is a 50% reduction in migraine days, but a 30–50% drop is still a meaningful improvement worth keeping. If a preventive truly isn't helping after an adequate trial, the answer is usually to switch to a different type rather than to conclude that prevention is hopeless. And there's genuine good news built into this: with effective prevention and by getting off overused acute medicines, many people with chronic migraine move back to having occasional (episodic) migraine. Chronic migraine is not necessarily permanent.

These medications were developed for other conditions and found to have migraine-preventive properties. They remain first-line options, especially when cost or insurance access barriers limit newer therapies:

• Beta-blockers: Propranolol (80–240 mg/day) and metoprolol (100–200 mg/day) have the strongest evidence. Well-suited for patients with coexisting hypertension or anxiety. Side effects include fatigue, exercise intolerance, and depression. Contraindicated in asthma.
• Topiramate (50–200 mg/day): An FDA-approved oral preventive for migraine (the FDA-approved oral preventives also include propranolol, timolol, and divalproex). Effective but carries significant side effects: cognitive impairment (“brain fog,” word-finding difficulty), weight loss, kidney stones, paresthesias, metabolic acidosis. Teratogenic (FDA Pregnancy Category D; associated with cleft lip/palate and small-for-gestational-age) — avoid in pregnancy or for women of childbearing potential not on reliable contraception.
• Amitriptyline (25–75 mg/day): Tricyclic antidepressant with good migraine evidence, especially useful when migraine coexists with insomnia or tension-type headache. Side effects include sedation, weight gain, dry mouth, constipation. Given at bedtime.
• Venlafaxine (75–150 mg/day): SNRI with moderate evidence for migraine prevention. Useful when migraine coexists with depression or anxiety.
• Valproate/divalproex (500–1500 mg/day): FDA-approved for migraine prevention. Effective but limited by side effects (weight gain, tremor, hair loss, liver toxicity) and teratogenicity (category X). Rarely used in women of childbearing potential.
• Candesartan (16 mg/day): An angiotensin receptor blocker with evidence comparable to propranolol in some studies. Well-tolerated. Useful for patients who also have hypertension.

An adequate trial of an oral preventive requires the target dose for at least 2–3 months before concluding it has failed. Many patients are underdosed or abandon treatment too early.

Most insurers require patients to try and fail 2–3 oral preventives before approving CGRP monoclonal antibodies or Botox. While frustrating, this means patients should systematically trial oral preventives at adequate doses for adequate durations, documenting the outcome and reason for discontinuation each time. This documentation is essential for eventual approval of newer therapies.

Headache specialists are experienced at navigating step therapy requirements and can structure the sequence strategically — for example, choosing oral preventives that also address comorbidities (beta-blocker for anxiety, amitriptyline for insomnia, topiramate when weight loss is desired).

For most of the history of migraine, “preventive” medicines were borrowed from other conditions — blood-pressure drugs, epilepsy drugs, antidepressants. They helped some people, but they were not designed for migraine and often came with side effects (weight change, fatigue, mental fog) that led people to stop them. The CGRP-targeted medicines are different: they are the first preventives built specifically around the biology of migraine, by blocking a molecule (CGRP) that is central to triggering attacks. That design shows up as a better experience — comparable or better prevention with far fewer of the bothersome side effects that drove people off the older drugs.

There are two forms, and which suits you is mostly about preference and access. The antibodies (erenumab, fremanezumab, and galcanezumab as self-given injections; eptinezumab as an IV infusion) are given monthly or every three months — convenient if you'd rather not take a daily pill. The gepant pills (atogepant daily, rimegepant every other day) suit people who prefer an oral medicine they can start and stop easily. Importantly, the major U.S. guidelines now say these can be used as a first preventive — you no longer have to fail several older drugs first — though your insurance may still require you to try cheaper options before it will pay.

Two expectations help. Give any of them an honest three-month trial before deciding it isn't working, and judge success concretely — a halving of your migraine days is the usual goal, but even a 30–50% reduction is a real, worthwhile gain. And if the first one doesn't help enough, that does not mean the whole class has failed: switching to a different CGRP medicine, or to Botox, helps many people who didn't respond to the first choice.

• Erenumab (Aimovig): FDA-approved May 2018. The first CGRP-targeted therapy approved. Blocks the CGRP receptor (the only mAb that targets the receptor rather than the ligand). Monthly subcutaneous autoinjector (70 mg or 140 mg). Proven effective for episodic and chronic migraine in the STRIVE (NCT02456740), ARISE (NCT02483585), and chronic migraine-specific studies. Side effects include injection-site reactions and constipation (more common with erenumab than other CGRP mAbs, likely due to the receptor-targeting mechanism).
• Fremanezumab (Ajovy): FDA-approved September 2018. Targets the CGRP ligand. Available as monthly (225 mg) or quarterly (675 mg) subcutaneous injection — the quarterly option reduces injection frequency. Proven in the HALO CM (NCT02621931) and HALO EM (NCT02629861) trials. The FOCUS trial (NCT03308968) demonstrated efficacy even in patients who had failed 2–4 prior preventive classes.
• Galcanezumab (Emgality): FDA-approved September 2018. Targets the CGRP ligand. Monthly subcutaneous injection (loading dose 240 mg, then 120 mg monthly). Proven in the EVOLVE-1 (NCT02614183), EVOLVE-2 (NCT02614196), and REGAIN (NCT02614261) trials. Also FDA-approved for episodic cluster headache. Demonstrated sustained efficacy in open-label extensions.
• Eptinezumab (Vyepti): FDA-approved February 2020. Targets the CGRP ligand. Quarterly intravenous infusion (100 mg or 300 mg over 30 minutes). The only IV-administered CGRP mAb. Proven in the PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) trials. Advantage: fastest onset of action among CGRP mAbs (significant reduction in migraine days starting on day 1 after infusion). Useful for patients who prefer quarterly dosing managed by a provider or who want rapid onset.

What patients should know about CGRP monoclonal antibodies:

• They are remarkably well-tolerated compared to oral preventives. The most common side effects are injection-site reactions and constipation (erenumab). They do not cause weight gain, cognitive impairment, or sedation.
• They work for patients who have failed multiple prior preventives — trials specifically enrolled these patients.
• Response should be assessed after 3 months of treatment. Some patients respond within the first month; others require the full 3-month trial.
• They can be used alongside oral preventives and Botox.
• Long-term safety data now extends to 5+ years with no new safety signals identified.
• Cost remains a barrier: list prices are approximately $600–700/month without insurance. Manufacturer copay assistance programs typically reduce out-of-pocket costs to $0–$5/month for commercially insured patients. Medicare patients have fewer assistance options.

• Atogepant (Qulipta): FDA-approved September 2021 for episodic migraine prevention, April 2023 for chronic migraine prevention. Daily oral tablet (10 mg, 30 mg, or 60 mg). Proven in the ADVANCE (NCT03777059) trial for episodic migraine and the PROGRESS (NCT03855137) trial for chronic migraine. The first oral CGRP antagonist approved specifically for prevention. Well-tolerated; main side effects are constipation and nausea. Dose adjustments needed with strong CYP3A4 inhibitors.
• Rimegepant (Nurtec ODT, 75 mg every other day): As noted in the acute section, rimegepant has a dual indication for both acute treatment and prevention. Proven for prevention in a dedicated trial (NCT03732638). The convenience of a single medication for both acute and preventive use is significant for many patients.

Botox for chronic migraine is not the same as cosmetic Botox, even though it is the same toxin. In migraine, it works by inhibiting the release of pain-signaling neuropeptides (including CGRP and substance P) from peripheral trigeminal nerve endings. It reduces peripheral sensitization, which in turn reduces the input driving central sensitization.

The PREEMPT 1 (NCT00156910) and PREEMPT 2 (NCT00168428) trials established the evidence base. Key facts:

• Protocol: 155–195 units injected across 31–39 sites in the forehead, temples, back of the head, neck, and upper shoulders. The injection session takes about 15 minutes.
• Frequency: Every 12 weeks (quarterly).
• Onset: Typically 2–4 weeks for noticeable effect. Full benefit may take 2–3 treatment cycles (6–9 months). Do not abandon Botox after a single cycle.
• Efficacy: Reduces headache days by an average of 8–9 per month in chronic migraine patients. Roughly 50% of patients achieve a 50% or greater reduction in headache days.
• Side effects: Neck pain, injection-site soreness, temporary muscle weakness (e.g., eyelid drooping, which occurs in about 2–4% and resolves in weeks), rarely flu-like symptoms.

Botox and CGRP monoclonal antibodies work through different mechanisms and can be used together. Several real-world studies and the prospective CONQUER trial data suggest that combination therapy (Botox plus a CGRP mAb) can provide additional benefit for patients with refractory chronic migraine who have not achieved adequate control with either alone. This is increasingly done in clinical practice, particularly in headache specialty centers.

• Am I using the right acute treatment for the severity of my attacks? Should I try a different triptan or formulation?
• Do I have cardiovascular risk factors that mean I should avoid triptans and consider gepants or lasmiditan instead?
• How many preventive medications have I tried, and do I now qualify for CGRP therapy or Botox through my insurance?
• What are the realistic side effects of this preventive, and how long should I trial it before we know if it works?
• Can we combine Botox with a CGRP monoclonal antibody if one alone is insufficient?
• Am I at risk for medication overuse headache with my current acute medication use? How many days per month should I limit it to?
• Should I be taking any of the evidence-based supplements (magnesium, riboflavin, CoQ10) alongside my prescription medications?
• If I am planning pregnancy, which of my current medications need to be stopped, and what alternatives are safe?

Neuromodulation devices — small units that deliver gentle electrical or magnetic stimulation to nerves involved in migraine — are a genuinely useful option, but it helps to have realistic expectations. Their biggest advantage is what they don't do: they add no drug to your body, which makes them especially valuable during pregnancy or breastfeeding, when you are already taking several medicines, or when medication-overuse headache is the problem and adding more pills is the last thing you need. Most are well tolerated, with side effects limited to mild tingling or discomfort where the device sits.

The honest trade-off is that, on average, the devices tend to help somewhat less than the most effective medicines, and they work best as part of a plan rather than as a sole treatment in straightforward cases. They also have to be used consistently — like any preventive, an unused device does nothing. Several can be used both to treat an attack and to prevent attacks, depending on the model.

The practical barriers are usually cost and coverage: insurance support is inconsistent, and some devices are bought directly by the patient. If you are drug-averse, pregnant, sensitive to medication side effects, or simply want to add a non-drug layer to your prevention, a device is a reasonable thing to ask about — just fold it into the same “give it a fair trial and track whether it helps” approach you would use for any preventive.

• Cefaly (external trigeminal nerve stimulation, eTNS): FDA-cleared for both acute treatment and prevention. A device worn on the forehead that stimulates the supraorbital branch of the trigeminal nerve. Acute mode: 60-minute session during an attack. Preventive mode: 20-minute daily session. Proven in the ACME (NCT02590939) trial for acute use and the EPIC trial for prevention. Prescription required. Available for purchase (~$400). Side effects: forehead tingling, sleepiness during use.
• gammaCore (non-invasive vagus nerve stimulation, nVNS): FDA-cleared for acute treatment and prevention of migraine and cluster headache. A handheld device applied to the neck over the vagus nerve. Two 2-minute stimulations per session. Studied in the PRESTO (NCT02686034) and EVENT trials. Prescription required (~$600/month lease). Side effects: mild neck tingling.
• SAVI Dual (single-pulse transcranial magnetic stimulation, sTMS): FDA-cleared for both acute treatment and prevention — the “dual” refers to this acute-plus-preventive use, not to two nerve targets. Held against the back of the head, it delivers brief, painless magnetic pulses to the occipital cortex. Non-invasive; cleared for ages 12 and older.
• SpringTMS / eNeura (single-pulse transcranial magnetic stimulation, sTMS): FDA-cleared for acute treatment, prevention, and treatment of aura. A device held against the back of the head that delivers a single magnetic pulse. Studied in the ESPOUSE trial. Prescription required. Available by subscription. Side effects: rare lightheadedness.
• Nerivio (remote electrical neuromodulation, REN): FDA-cleared for acute treatment. A smartphone-controlled armband that stimulates conditioned pain modulation pathways. Applied to the upper arm during an attack for 45 minutes. Studied in the PRIME trial. Available by prescription (~$99/month). Advantages: can be used discreetly in any setting.

Neuromodulation devices are particularly useful for: patients who want to reduce medication use, pregnant patients (no systemic drug exposure), patients with contraindications to multiple drug classes, and as adjuncts to pharmacological treatment.

Migraine attracts an enormous amount of lifestyle advice, much of it well-meaning but unproven, and it helps to know where the real evidence lies so you can spend your energy on what works. The best-supported lifestyle levers are unglamorous but genuinely effective: regular sleep (a consistent schedule — both too little and oversleeping can trigger attacks), not skipping meals and staying hydrated, regular aerobic exercise (which has trial support as a preventive in its own right), and steady, moderate caffeine rather than erratic use. Stress itself is a trigger, but so is the “let-down” period right after stress — which is why migraines so often strike on the first day of a weekend or vacation.

The popular idea of hunting for and eliminating dietary “trigger foods” deserves a more careful take. Triggers are real but highly individual, frequently additive (no single thing tips you over, but several together do), and easily confused with premonitory cravings — the chocolate or carbohydrate you reach for may be an early symptom of an attack already beginning, not its cause. Rigid elimination diets often shrink life without reducing attacks. A short, focused diary period to test one specific suspected trigger is more useful than blanket avoidance.

Among supplements, magnesium, riboflavin (vitamin B2), and coenzyme Q10 have modest but real preventive evidence and a good safety profile, and are reasonable to discuss — particularly in pregnancy or when you want to minimize medication. Behavioral therapies (cognitive behavioral therapy, biofeedback, relaxation training) are among the most evidence-based of all non-drug approaches and are especially valuable given how tightly migraine, sleep, and mood are linked. The honest summary: lifestyle measures are a genuine part of treatment, but they work best alongside effective medical therapy, not as a substitute that delays it.

The American Headache Society promotes the SEEDS mnemonic for lifestyle management:

• S — Sleep: Regular sleep-wake schedule (same bedtime and wake time 7 days a week) is one of the most impactful interventions. CBT for insomnia (CBT-I) has evidence specifically in migraine. Treat sleep apnea if present — it is an independent migraine aggravator.
• E — Exercise: Regular aerobic exercise (30–40 minutes, 3–5 times per week) has evidence comparable to topiramate for migraine prevention. A key challenge: exercise is itself a migraine trigger for some patients during high-frequency periods. Start gradually and build up.
• E — Eat regularly: Skipping meals is a reliable migraine trigger. Consistent meal timing matters more than specific diets. Stay well-hydrated. Eliminate or reduce caffeine gradually (abrupt withdrawal triggers headache). The evidence for specific elimination diets (gluten-free, low-tyramine) is limited for most patients.
• D — Diary: Track headache days, migraine features, acute medication use, triggers, and disability. This data drives treatment decisions.
• S — Stress management: Stress is the most commonly reported trigger, but the relationship is complex — the “let-down” period after stress may be more provocative than stress itself. Cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and biofeedback all have evidence in migraine. Biofeedback has Level A evidence from the AAN.

Commonly reported triggers include: stress and stress let-down, sleep disruption, skipping meals, weather changes, hormonal fluctuations, alcohol (especially red wine), strong odors, bright or flickering lights, and loud sounds.

An important nuance about triggers: The relationship between triggers and attacks is more complex than simple cause-and-effect. Many reported “triggers” may actually be prodromal symptoms of an already-beginning attack (e.g., food cravings during the prodrome are mistaken for the food being the trigger). Overaggressive trigger avoidance can lead to a progressively restricted, fear-driven life that increases disability without reducing attacks. The goal is to manage genuine, consistent triggers (especially sleep, meals, and hydration) without building an ever-growing avoidance list.

Several supplements have evidence supporting their use in migraine prevention, though the evidence is generally weaker than for prescription medications:

• Magnesium (400–600 mg daily, citrate or oxide form): AAN Level B evidence. Effective, especially in migraine with aura. Well-tolerated; main side effect is diarrhea at higher doses. Magnesium deficiency is common in migraine patients.
• Riboflavin / Vitamin B2 (400 mg daily): AAN Level B evidence. Very well-tolerated. May take 3 months to show effect. Urine turns bright yellow — harmless.
• Coenzyme Q10 (100 mg three times daily): AAN Level C evidence. Well-tolerated. May have additional benefit for patients with mitochondrial dysfunction.
• Feverfew (50–300 mg daily, standardized extract): Mixed evidence. Some positive trials, some negative. Generally well-tolerated.
• Butterbur (Petadolex): Previously recommended (AAN Level A evidence) but withdrawn from the US market due to hepatotoxicity concerns from unregulated preparations. Only purified PA-free formulations are considered acceptable, and availability is limited. Most headache specialists no longer actively recommend it.

Supplements should be discussed with the treating provider. They are best used as adjuncts to, not replacements for, evidence-based preventive therapy.

If you have tried multiple treatments without enough relief, it is easy to conclude that nothing will ever help — but the reality of migraine research right now argues strongly against that despair. The pipeline is the most active it has ever been, and crucially, the newest experimental treatments work through different mechanisms than the ones you may already have tried. The most promising is a class aimed at a molecule called PACAP, a cousin of CGRP that triggers migraine through partly separate pathways. In early studies an anti-PACAP treatment helped people who had already failed several preventives — exactly the group that most needs a genuinely new option — which suggests that “the CGRP drugs didn't work for me” will not mean “out of options” for much longer.

This matters for how you think about clinical trials. Far from being a last resort for the desperate, trials are often the fastest route to a genuinely novel treatment for someone whose migraine has resisted the standard ones — and the treatments that are standard today, including the CGRP medicines, were available only through trials a few years ago. If you have run out of approved options, ask your clinician or a headache center specifically whether a trial is open for you, and search ClinicalTrials.gov.

Two grounded notes temper the hope without removing it. New treatments take years to prove themselves, and not every promising early result holds up — so treat any single headline as one step, not a finish line. But the direction of travel is unmistakable: migraine has gone from a field with almost no purpose-built treatments to one with several, and more on the way. For a person living with chronic migraine, that trajectory is a realistic basis for hope.

Atogepant (Qulipta) received FDA approval for chronic migraine prevention on April 17, 2023 based on the PROGRESS trial (NCT03855137). This was a 12-week, randomized, double-blind, placebo-controlled study of 778 patients with chronic migraine. Atogepant 60 mg once daily reduced monthly migraine days by 7.5 versus 5.1 with placebo — a clinically meaningful difference. This extends atogepant’s role from episodic to chronic migraine, providing the first oral CGRP receptor antagonist specifically approved for chronic migraine prevention.

While already FDA-approved, eptinezumab (Vyepti) continues to differentiate itself through its quarterly IV dosing and rapid onset. The DELIVER trial (NCT04418765) specifically studied eptinezumab in patients who had failed 2–4 prior preventive treatments, showing significant efficacy even in this difficult-to-treat population. The 300 mg dose reduced migraine days by 7.7 versus 5.6 for placebo. Real-world data suggest that some patients who do not respond to subcutaneous CGRP mAbs may respond to eptinezumab, possibly due to the higher Cmax achieved with IV dosing.

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide, like CGRP, that is elevated during migraine attacks and can provoke migraine when infused. Anti-PACAP monoclonal antibodies are in clinical development as the next major neuropeptide target after CGRP. Lu AG09222, an anti-PAC1 receptor antibody, has shown positive Phase 2 results. If successful, this would provide a completely new mechanism for patients who do not respond to CGRP-targeted therapy.

Next-generation neuromodulation approaches under investigation include:

• Closed-loop stimulation systems: Devices that detect the onset of a migraine attack and automatically deliver stimulation, rather than requiring patient-initiated treatment.
• Single-pulse transcranial magnetic stimulation (SAVI Dual): Delivers brief magnetic pulses over the occipital cortex to interrupt cortical spreading depression; FDA-cleared for both acute and preventive use.
• Invasive occipital nerve stimulation (ONS): Implanted stimulators for highly refractory chronic migraine. Reserved for patients who have failed all standard therapies. Limited evidence and high cost.

• Orexin receptor antagonists: Dual orexin receptor antagonists (DORAs), currently approved for insomnia (e.g., suvorexant), are being investigated for migraine prevention, given the link between sleep regulation and migraine.
• Glutamate receptor modulators: Targeting the glutamatergic system, which plays a role in cortical spreading depression and central sensitization.
• Nitric oxide synthase inhibitors: Blocking nitric oxide production, a known migraine trigger pathway.
• Gene therapy approaches: Very early-stage research into modifying CGRP expression or trigeminal nerve sensitization at the genetic level.

• Am I considered refractory to current treatments? At what point should we discuss more aggressive options?
• Are there clinical trials at your center or nearby that I might be eligible for?
• Would PACAP-targeted or other next-generation therapies potentially be available to me through trials?
• Is neuromodulation (Cefaly, gammaCore, Nerivio) a reasonable addition to my current treatment plan?
• Have I tried all available CGRP-targeting approaches (switching between mAbs, trying a gepant, combining Botox)?
• Is there anything about my migraine pattern that suggests I should try a specific emerging approach?

• Telcagepant and other first-generation gepants (oral) FAILED
  Telcagepant (MK-0974) was the first oral CGRP receptor antagonist to reach Phase III trials. Development was halted due to liver toxicity with daily dosing. The second-generation gepants (ubrogepant, rimegepant, atogepant) were specifically engineered to avoid this hepatotoxicity, and none have shown similar liver concerns.
• Opioids for routine migraine treatment DE-ADOPTED
  Opioids were once commonly prescribed for severe migraine. They are now recognized as counter-therapeutic: they do not address migraine pathophysiology, have the highest risk of MOH among all drug classes, increase the risk of chronic migraine progression, interfere with the efficacy of other migraine treatments, and carry addiction risk. AHS and AAN guidelines recommend against routine opioid use for migraine.
• Butalbital-containing compounds for routine use DE-ADOPTED
  Fioricet (butalbital/acetaminophen/caffeine) and Fiorinal (butalbital/aspirin/caffeine) are still prescribed but are not recommended by any major headache guideline for routine use. High risk of MOH, dependency, and limited evidence of superiority over simpler analgesics.
• Patent foramen ovale (PFO) closure for migraine FAILED
  Several randomized controlled trials (MIST, PRIMA, PREMIUM) tested closure of PFO (a common heart defect) as a migraine treatment, based on observational associations. None demonstrated a significant reduction in migraine frequency. PFO closure is not recommended for migraine.
• Surgical decompression of peripheral trigger sites (migraine surgery) FAILED
  Surgical decompression of nerves in the forehead, temple, and occipital regions was promoted as a migraine cure. The evidence comes from poorly controlled studies with high placebo response rates and significant methodological concerns. Not recommended by any major headache society. The American Headache Society has issued a position statement against migraine surgery.
• Daith piercing NO EVIDENCE
  Piercing of the ear’s daith cartilage has been promoted on social media as a migraine treatment based on claimed similarity to acupuncture points. There is no clinical trial evidence supporting this. Any reported benefit is consistent with placebo response. Risks include infection and scarring.

One of the hardest parts of chronic migraine is that it is invisible. Between attacks you may look completely well, which makes it difficult for employers, colleagues, and even family to grasp that you live with a disabling neurological disease. This gap — feeling judged as unreliable or as exaggerating — is a real source of stress and isolation, and naming it is the first step to managing it. You are not imagining the difficulty: chronic migraine is consistently ranked among the most disabling conditions worldwide.

At work, modest accommodations often make the difference between coping and not. Reasonable adjustments — reduced screen glare, control over harsh fluorescent lighting, a quiet space to take a rescue medication, flexibility to make up time lost to an attack, and the ability to work from home on bad days — are frequently enough to keep people productive. In the United States and many other countries, chronic migraine can qualify as a disability for the purpose of requesting workplace accommodations; a letter from your clinician describing your needs is the usual starting point, and your headache diary documents the pattern if you ever need to formalize it.

In relationships, the most useful move is to explain the disease in concrete terms to the people close to you — what an attack is, what you need during one (often quiet, dark, and to be left to treat it early), and that cancelling plans is the migraine talking, not a lack of interest. Connecting with others who have migraine, through patient organizations or support communities, counters the isolation and is a good source of practical coping strategies. And because depression and anxiety travel with chronic migraine and worsen it, treating your mental health is part of treating your migraine — not a separate or lesser concern.

Depression and anxiety are roughly three times more common in people with chronic migraine than in the general population. This is not weakness — it is a bidirectional biological relationship. Depression makes migraine worse, and migraine makes depression worse. Untreated psychiatric comorbidity is one of the strongest predictors of preventive treatment failure.

Treatment of coexisting depression and anxiety is a direct migraine treatment strategy. CBT has specific evidence in migraine. Some preventive medications (amitriptyline, venlafaxine) treat both conditions simultaneously. Discuss mental health screening with your headache specialist.

Chronic migraine is a leading cause of workplace disability. Practical strategies include:

• Requesting ADA reasonable accommodations: flexible scheduling, work-from-home options, lighting adjustments, quiet workspace
• FMLA protection: chronic migraine qualifies as a serious health condition for intermittent leave
• If disability is severe: Social Security Disability Insurance (SSDI) is available for chronic migraine with documented functional limitations. The application process requires thorough medical documentation — headache diaries, MIDAS scores, treatment history, and specialist records
• Document everything: headache frequency, missed work days, functional limitations. This documentation supports both workplace accommodations and any future disability claims

Migraine management during pregnancy requires careful planning:

• Migraine often improves during pregnancy (especially in the second and third trimesters), particularly migraine without aura. This improvement is driven by stable estrogen levels.
• Most preventive medications must be stopped before or during pregnancy. Topiramate and valproate are absolutely contraindicated (teratogenic).
• Safe acute options during pregnancy: acetaminophen, metoclopramide, certain nerve blocks (greater occipital nerve block with lidocaine), neuromodulation devices
• Safe preventive options during pregnancy: propranolol (with monitoring), magnesium supplementation, greater occipital nerve blocks, neuromodulation devices
• CGRP monoclonal antibodies: limited pregnancy data; generally discontinued before conception as a precaution. Their long half-lives mean they persist in the body for months after the last dose.
• Botox: category C; generally avoided during pregnancy, though inadvertent exposure has not shown clear adverse effects.
• Breastfeeding considerations vary by medication. Sumatriptan is considered compatible with breastfeeding.

Pre-conception planning with a headache specialist and obstetrician together is strongly recommended.

Chronic migraine affects the entire household. Family members should understand that migraine is a neurological disease, not a behavioral choice or attitude problem. Practical support includes: learning to recognize the patient’s prodromal signs, helping maintain environmental control (lighting, noise) during attacks, sharing household responsibilities during high-frequency periods, and understanding that plans may need to change with short notice. Family therapy or education sessions at headache centers can help.

• Based on my headache diary, do I meet criteria for chronic migraine?
• Am I overusing acute medications? If so, what is the plan for withdrawal?
• Do I need brain imaging, and if so, what are we looking for?
• Are there secondary causes of headache we should rule out?
• What preventive treatment do you recommend as a first step, and why?
• How long should I trial this treatment before we know if it is working?
• Should I be screened for depression, anxiety, or sleep disorders?

• How many preventive medications have I tried, and do I qualify for CGRP therapy or Botox through my insurance?
• What is the expected timeline for response with this preventive?
• What are the realistic side effects, and how will we manage them?
• Can we combine Botox with a CGRP monoclonal antibody if one alone is not sufficient?
• Are there clinical trials I should consider?
• How will we define “success” — what reduction in headache days is our target?

• Am I using the right acute treatment for the severity of my attacks?
• Have I tried enough different triptans, or should I try a different one or a different formulation?
• Would a gepant or lasmiditan be appropriate for me, given my medical history?
• How many days per month is it safe for me to use acute medication?
• What should I do when my acute treatment does not work?

• Is my chronic migraine likely to improve over time, or is this my new baseline?
• What lifestyle changes would you prioritize for me specifically?
• Should I see a psychologist or psychiatrist for the depression/anxiety that accompanies my migraine?
• How should we handle my migraine if I am planning pregnancy?
• At what point should we consider this refractory and pursue more aggressive options?
• What is the most useful thing my family can do to support me?

• Aimovig (erenumab) Ally program: For commercially insured patients. May reduce copay to $0–$5/month. aimovig.com
• Ajovy (fremanezumab) Savings Program: For commercially insured patients. ajovy.com
• Emgality (galcanezumab) Savings Card: For commercially insured patients. emgality.com
• Vyepti (eptinezumab) Patient Support: vyepti.com
• Qulipta (atogepant) Savings Program: qulipta.com
• Nurtec ODT (rimegepant) Savings Program: nurtec.com
• Ubrelvy (ubrogepant) Savings Program: ubrelvy.com

Note: manufacturer copay programs typically do not cover Medicare or Medicaid patients due to federal anti-kickback regulations. Medicare patients should ask about Patient Assistance Programs (PAPs) that provide the medication free of charge to qualifying individuals.

• NeedyMeds — database of prescription-assistance programs. 800-503-6897. needymeds.org
• Patient Advocate Foundation — case management, copay relief, appeals assistance. 800-532-5274. patientadvocate.org
• HealthWell Foundation — copay assistance for specific drugs. 800-675-8416. healthwellfoundation.org
• PAN Foundation — copay assistance. 866-316-7263. panfoundation.org

• American Migraine Foundation — patient education, provider finder, research support. americanmigrainefoundation.org
• Coalition for Headache and Migraine Patients (CHAMP) — advocacy, policy, patient community. headachemigraine.org
• Miles for Migraine — community events, support, education. milesformigraine.org
• Association of Migraine Disorders — research funding, patient education, clinical trial information. migrainedisorders.org
• National Headache Foundation — education and support. 888-643-5552. headaches.org

EM = episodic migraine; CM = chronic migraine. Dates shown are initial approval dates; supplemental indications may have been added later. “—” indicates not approved or not available in that jurisdiction as of mid-2026. Verify current regulatory status with each authority’s official database.

The US has the broadest range of approved migraine therapies. All four CGRP monoclonal antibodies, three oral gepants, lasmiditan, onabotulinumtoxinA (Botox), and multiple neuromodulation devices are available. Step therapy requirements vary by insurer but typically require 2–3 oral preventive failures before CGRP therapy approval. The AHS Consensus Statement and AAN Practice Guidelines are the primary clinical references.

The EMA has approved erenumab, fremanezumab, galcanezumab, and eptinezumab. In the UK, NICE technology appraisals have recommended CGRP mAbs for chronic and episodic migraine under specific criteria (typically after failure of 3+ preventives). Botox is available through the NHS for chronic migraine under defined criteria. Gepants and lasmiditan have more limited availability in Europe compared to the US. The European Headache Federation (EHF) guidelines guide clinical practice across the continent.

Health Canada has approved erenumab, fremanezumab, galcanezumab, and eptinezumab. Provincial formulary coverage varies. Several provinces require failure of 2–3 prior preventives for public coverage. Private insurance plans have variable coverage policies. Manufacturer patient support programs are available and widely used to bridge coverage gaps.

Japan: Erenumab, fremanezumab, and galcanezumab are approved by the PMDA. Japan contributed significantly to global CGRP clinical trials. The Japanese Headache Society guidelines align broadly with international standards. Gepant availability is more limited than in the US.

Australia: CGRP monoclonal antibodies are TGA-approved and available through the PBS for patients who meet chronic migraine criteria and have failed prior preventives. The Headache Australia organization provides patient education and provider directories.

• Insurance barriers: Step therapy requirements delay access to CGRP therapies and Botox. Document all failed trials carefully. Ask your provider about peer-to-peer review with insurance medical directors to expedite prior authorizations. The American Headache Society provides template appeal letters.
• Cost of newer therapies: CGRP mAbs list at $600–$700/month. Use manufacturer copay programs (see Financial Resources section). For uninsured/underinsured patients, Patient Assistance Programs (PAPs) from manufacturers can provide medication at no cost. 340B drug pricing programs at qualifying clinics may also reduce costs.
• Transportation: Many headache centers now offer telemedicine consultations. Eptinezumab (quarterly IV) requires in-office visits, but the other CGRP mAbs can be self-administered at home after initial training. Medicaid transportation assistance may be available in your state.
• Language and health literacy: Ask your headache center about interpreter services. The American Migraine Foundation provides patient education materials in multiple languages. Trouvera’s guide translation feature (language toggle at top) can help with basic comprehension.
• Rural access: Headache specialists are concentrated in urban areas. Telemedicine has expanded access significantly. The Jefferson Headache Center and Mayo Clinic both offer remote consultation programs. The American Migraine Foundation Provider Finder can identify the nearest specialist.
• Disability and employment: Chronic migraine qualifies for ADA accommodations and FMLA protection. Social Security disability is available for severe cases with documented functional limitations. The Patient Advocate Foundation (800-532-5274) provides free case management for insurance and employment issues.

• Why some patients respond dramatically to one CGRP monoclonal antibody but not another, despite similar mechanisms, is not fully understood. There are no reliable predictors of which CGRP therapy will work for which patient.
• The optimal duration of CGRP monoclonal antibody treatment is unknown. How long should a patient remain on therapy before attempting to taper? Current guidance suggests assessing after 6–12 months of good control, but evidence is limited.
• Whether CGRP-targeted therapies truly have a lower MOH risk than triptans, or whether this is an artifact of shorter follow-up and different study designs, is not definitively established.
• The mechanism by which onabotulinumtoxinA (Botox) works in chronic migraine but not episodic migraine is not fully understood.
• Why chronic migraine develops in some people with episodic migraine but not others — and why some revert to episodic while others do not — remains incompletely explained by current models.
• The role of neuroinflammation, the glymphatic system, and the gut-brain axis in migraine are active research areas with no definitive conclusions yet.

It is not uncertain that migraine is a real neurological disease with a biological basis. It is not uncertain that CGRP plays a central role in migraine pathophysiology. It is not uncertain that medication overuse drives chronification and that addressing it improves outcomes. It is not uncertain that CGRP-targeted therapies, onabotulinumtoxinA, and established oral preventives reduce migraine frequency when properly used. It is not uncertain that lifestyle factors — particularly sleep regularity, exercise, and stress management — have measurable impact on migraine frequency. And it is not uncertain that specialist headache care produces better outcomes than generalist management. These facts are the foundation for genuine, evidence-based hope in chronic migraine treatment.

• Allodynia — pain from a stimulus that is normally not painful, such as brushing hair, wearing a hat, or touching the face. A sign of central sensitization in chronic migraine.
• Aura — reversible neurological symptoms (usually visual) that develop gradually before or during a migraine attack, lasting 5–60 minutes.
• CGRP (Calcitonin Gene-Related Peptide) — a neuropeptide released during migraine attacks that plays a central role in migraine pain. The target of the newest migraine therapies.
• Central sensitization — amplification of pain signals in the central nervous system, making the brain more responsive to pain. A hallmark of chronic migraine.
• Chronic migraine — 15 or more headache days per month for at least 3 months, with at least 8 days having migraine features.
• Cortical spreading depression (CSD) — a wave of neuronal activity followed by suppression that spreads across the brain cortex, causing aura symptoms.
• Ditan — a class of acute migraine drugs (e.g., lasmiditan) that activate serotonin 5-HT1F receptors without causing blood vessel constriction.

• Episodic migraine — fewer than 15 headache days per month. The more common form of migraine.
• Gepant — a class of small-molecule drugs (ubrogepant, rimegepant, atogepant, zavegepant) that block the CGRP receptor. Used for acute treatment and/or prevention.
• Hemiplegic migraine — a migraine subtype that includes temporary motor weakness (hemiplegia) as part of the aura.
• ICHD-3 — International Classification of Headache Disorders, 3rd edition. The global standard for classifying and diagnosing headache disorders.
• Medication overuse headache (MOH) — headache occurring on 15 or more days per month in a patient with a pre-existing headache disorder who regularly overuses acute headache medication for more than 3 months.
• HIT-6 (Headache Impact Test) — a six-question validated survey measuring headache impact on daily life, including pain, functioning, vitality, and emotional distress. Scores above 60 indicate substantial impact.
• MIDAS — Migraine Disability Assessment. A validated questionnaire measuring migraine-related disability over the past 3 months.
• Monoclonal antibody (mAb) — a laboratory-made protein that targets a specific molecule. In migraine, CGRP monoclonal antibodies block CGRP or its receptor.

• Neuromodulation — using electrical or magnetic stimulation of nerves to modify pain signaling. Available as FDA-cleared devices for migraine.
• Abortive (acute) treatment — a medication or intervention taken during a migraine attack to stop or reduce it. Examples: triptans, gepants, lasmiditan, NSAIDs.
• Prophylactic (preventive) treatment — a medication or intervention taken regularly (daily, monthly, or quarterly) to reduce the frequency and severity of future migraine attacks. Examples: CGRP mAbs, Botox, topiramate, beta-blockers.
• OnabotulinumtoxinA (Botox) — botulinum toxin type A, injected at specific head and neck sites every 12 weeks for chronic migraine prevention.
• Photophobia — increased sensitivity to light, a hallmark symptom of migraine.
• Phonophobia — increased sensitivity to sound during a migraine attack.
• Prodrome — the earliest phase of a migraine attack, occurring hours to days before the headache, with symptoms like fatigue, mood changes, and food cravings.
• Postdrome — the recovery phase after a migraine headache, often involving fatigue and cognitive difficulty (“migraine hangover”).
• Scotoma — an area of lost or altered vision, often occurring during migraine aura.
• Step therapy — an insurance requirement to try and fail cheaper medications before being approved for newer, more expensive treatments.
• Trigeminovascular system — the network of trigeminal nerve fibers and blood vessels in the brain that is the primary pain generator in migraine.
• Triptan — a class of acute migraine drugs (sumatriptan, rizatriptan, etc.) that activate serotonin 5-HT1B/1D receptors. The most widely used migraine-specific acute treatment.
• Vestibular migraine — a migraine subtype characterized by episodes of vertigo associated with migraine features.

Guidelines:

• International Classification of Headache Disorders, 3rd edition (ICHD-3) — International Headache Society
• American Headache Society (AHS) Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice
• AAN/AHS Practice Guideline: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
• AHS Position Statement: The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice (2019, updated)
• European Headache Federation (EHF) Guideline on the Use of Monoclonal Antibodies Acting on the CGRP Pathway or Its Receptor

Landmark trials referenced in this guide:

• American Migraine Foundation (americanmigrainefoundation.org) — Patient education, provider finder, clinical trial information
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials
• National Headache Foundation (headaches.org) — 888-643-5552. Education and support
• Coalition for Headache and Migraine Patients (CHAMP) (headachemigraine.org) — Advocacy and patient community
• Miles for Migraine (milesformigraine.org) — Community events and support
• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research